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The present opinion is the result of discussions on the future of
phage therapy (personalized or large-scale uniform therapy?)
during the first International Congress on Viruses of Microbes,
held at the Institut Pasteur in Paris on June 21–25, 2010.
Antibiotics are becoming ineffective as important bacterial
pathogens evolve to outsmart them. Yet the antibiotic pipeline
is running dry with only a few new antibacterial drugs
expected to make it to the market in the foreseeable future.
Bacteria that are resistant to all available antibacterial drugs,
so-called superbugs, are emerging worldwide. Evolutionary
ecology might inform practical attempts to bring these
pathogens under stronger human control (1).
In this context, various laboratories worldwide and a
handful of small pharmaceutical companies are turning to
(bacterio)phages (2). Phages are natural viruses that
specifically infect bacteria. They are (among) the most
abundant and ubiquitous lifelike entities on Earth and
coevolve with their hosts, the bacteria. Lytic phages bind to
receptors on the bacterial cell surface, inject their genetic
material, use the bacterium’s reproductive machinery to
replicate and subsequently destroy (lyse) the bacterium,
irrespective of its resistance to antibiotics, releasing the
newly formed phages to seek out new hosts.
In 1919, d’Herelle used phages to treat dysentery in
Paris, in what was probably the first attempt to use phages
therapeutically. d’Herelle eventually developed a commercial
laboratory in Paris that produced phage preparations against
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various bacterial infections, which were marketed by what
later became the large French company L’Oréal (3). In the
1930s, therapeutic phages were also marketed in the United
States by major pharmaceutical companies including Eli
Lilly, Squibb & Sons (today Bristol-Meyers Squibb) and the
Swan-Meyers division of Abbott Laboratories. Scientific
controversies and the advent of antibiotics, however,
relegated phage therapy to complete obscurity in most of
the Western world. Nevertheless, phage therapy was further
developed and extensively used in Eastern Europe and the
former Soviet Union with activities centered at the Eliava
Institute of Bacteriophage, Microbiology, and Virology
(EIBMV) in Tbilisi, Georgia, several institutes in Russia,
and the Hirszfeld Institute of Immunology and Experimental
Therapy in Wroclaw, Poland.
Despite its long (Eastern European) history, phage therapy
is not currently authorized for routine use on humans in the
West. Today, it is only approved in some former Soviet
republics like Russia and Georgia, where commercial phage
preparations are sold in pharmacies (4). In Poland, a recent
member of the European Union, phage therapy is consid-
ered an ‘Experimental Treatment’ covered by the Physician
Practice Act (Polish Law Gazette N° 28 of 1997) and the
declaration of Helsinki, where other therapeutic options do
not exist (5). In France, therapeutic made-to-order phage
preparations from the Institut Pasteur (Paris and Lyon) were
used until the beginning of the nineties. Today, a French
practitioner, Alain Dublanchet, still uses commercial phage
preparations (purchased in Russia and Georgia) to treat
severe infections. Despite the absence of a specific framework
for phage therapy (6), a pilot clinical trial in burn wounds
was approved by a leading ethical committee in Belgium (7).
In the United States, a Food and Drug Administration
(FDA)-approved phase I clinical trial was conducted. No
safety concerns were found (7). Recently, a British phage
therapy company conducted a phase I/IIa clinical trial in
chronic otitis. This study was approved through the UK
Medicines and Healthcare products Regulatory Agency
(MHRA) and the Central Office for Research Ethics
Committees (COREC) ethical review process (7).
Phages are harmless to eukaryotic (e.g. animal or
plant) cells and are reported to elicit few, if any, side
effects in humans. In contrast to antibiotics, they target
specific bacterial species or even strains and can thus be
chosen to be harmless for the non-target beneficial
commensal flora (e.g. the gut flora) of the patient. This
specificity also means that the right match between the
phages and the targeted bacterial pathogen must be
found. To improve the chance of success, off-the-shelf
phage preparations should contain multiple phage strains
per targeted bacterial species. This phage mixture should
target the bacterial strains that are most commonly
present at the intended point of use.
As with antibiotics, bacteria can evolve resistance to
phages during the course of treatment (e.g. by alteration of
phage receptors), to survive the phage attacks. This might
result from mutations acquired during the course of
treatment, but it is also likely that resistant bacteria are
already present in the target population before phage
treatment. Indeed, it is not in phages’ best interest to kill all
the host bacteria in the infection site, but they can be
expected to (bio)control the bacterial pathogens and
significantly reduce their numbers and thus give the
patient’s immune system and/or antibiotics the chance to
eliminate the remaining bacteria. Moreover, in vitro, natural
selection drives the rapid emergence of new phages that can
destroy bacteria that have become resistant (9), and this
may also be important in clinical contexts.
Ninety years of phage therapy have shown that after a
while phage preparations become less effective and need to
be updated. The ineffective phages can either be “trained,”
a term used in the EIBMV to indicate the selection of
phage mutants more active against the phage-resistant
bacteria, or replaced by new active phages. New phages
are generally selected from the environment (e.g. sewage
water), but in some cases they can be isolated from clinical
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samples containing the problematic bacterium. In phage
therapy centers in Georgia and Poland, banks containing
many different phages are kept and regularly updated.
Sometimes custom phage preparations are developed for a
patient’s infection (autophage), a procedure that usually
takes a few days to weeks.
This sur-mesure approach is not compatible with the
current licensing processes. Recently, the European Med-
icines Agency (EMA) placed phages under the Medicinal
Product Regulation and more specifically under the
category of biologicals. Also, in the US, the amount of
research and testing required by the FDA is seriously
hampering the resurgence of phage therapy. Regulators
impose many years of research and clinical trials, which cost
millions of euros, to entrepreneurs to develop and distribute
phage preparations (Fig. 1).
Fig. 1 Phage therapy concepts: prêt-à-porter or sur-mesure? Both approaches should be possible and could even be complementary. The specificity of
phages, resistance and IP issues may thus hamstring pharmaceutical companies in the worldwide marketing of generic phage preparations. The long and
expensive regulatory pathways, on the other hand, form insurmountable obstacles for bonafide or non-profit phage therapy centers or hospitals, which opt
for a sur-mesure concept, and for institutions that would like to use inexpensive phages for commercially unattractive applications, in emerging countries,
for example. Of course, this sur-mesure approach should also adhere to certain standards of behavior, safety and quality control (8). These standards could
be defined in a new and specific section for phage therapy under the Advanced Therapy Medicinal Product Regulation (6).
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Notwithstanding these regulatory hurdles and the
empirical evidence suggesting that stable and widely
distributed phage preparations (prêt-à-porter) will only be
of (time-)limited use, a few companies have picked up the
gauntlet and are moving along the elaborate and
expensive licensing pathways. If nothing else, these efforts
will put phage therapy back on the map in the Western
world, and, once commonly accepted, EMA and FDA
might revise their rules the way they did for influenza
vaccines, which also require a rapid updating and
licensing procedure (10). However, are pharmaceutical
companies willing to commit to rapidly and regularly
adapting their phage preparations to very specific or
newly emerging demands? Take, for example, a hospital
unit confronted with an MDR bacterial strain that causes
untreatable infections in only one or two patients. Phage
therapy is probably best—but not exclusively—served by
small-scale productions and distributions of locally adapted or
personalized phage preparations (cottage industry) (Fig. 1).
To avoid the drug licensing pathway, some US-based
phage companies decided to first develop phage products
for the decontamination of food, plants, fields and livestock
(2). They hope to create revenue to fund research into
human therapeutics and to familiarize the authorities and
the general public with phages. Phages for decontaminating
food plants, ready-to-eat meat, poultry products, cheese
and live animals that will be slaughtered for human
consumption were approved by the FDA and are now in
use. Very little is known, however, about the impact of such
massive and widespread applications of phages on natural
microbial communities.
The lack of strong intellectual property (IP) protection
is another discouraging factor for pharmaceutical com-
panies. The principle of phage therapy has been
common knowledge since the 1920s, and many aspects
might thus be unpatentable. In addition, there are
indications that in the future, phages, which are natural
entities composed of genetic material and proteins, will
only be patentable if they have been engineered into
something distinctly different in character (11). Engi-
neered phages could be patented, but, considering the
current concerns about potential risks for public health
and the environment which may arise from genetic
engineering in genetically modified organisms (GMOs),
they are not likely to be given licensing approval in the
near future. Phage-derived products (e.g. cell wall-degrading
enzymes such as endolysins) can and probably will be
licensed and marketed within a few years. They may also
select resistance, but presumably at a lower rate than
antibiotics. Of course, these phage products lack the capacity
of self-replication and adaptation in the infectious site.
Phage therapy has great potential in some (niche) clinical
contexts, but as with antibiotic treatment, there are likely to be
important evolutionary consequences (12) if it is implemented
widely and without sufficient oversight. Some aspects of phage-
bacterium evolution ecology (e.g. emergence of resistance)
should first be analyzed in the light of future phage therapy.
Real-time experimental evolution studies could help determine
these evolutionary consequences and generate the analytical
knowledge in support of the empirical knowledge and clinical
experience that was accumulated in the Eastern world. More
importantly, they will hopefully enable the creation of a
rational phage therapy concept (Fig. 1), thus avoiding the
historical mistakes that occurred in the course of antibiotic
therapy development and which lead to the current massive
and widespread occurrence of antibiotic resistance in the
patient population as well as in the natural environment.
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